A type i interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis

Brain

Volumn 132, Issue 12, 2009, Pages 3353-3365

  Comabella, M ^a   Lunemann J D ^b,h   Rio J ^a   Sanchez A ^c   Lopez C ^a   Julia E ^a   Fernandez M ^a   Nonell, L ^a   Camina Tato M ^a   Deisenhammer, F ^d   Caballero, E ^e   Tortola, M T ^e   Prinz, M ^f   Montalban, X ^a   Martin, R ^g,i  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITY OF FREIBURG   (Germany)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^h INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Gene expression signature; Interferon beta; Monocytes; Multiple sclerosis

Indexed keywords

BETA INTERFERON; INTERFERON; INTERFERON RECEPTOR; STAT1 PROTEIN; TOLL LIKE RECEPTOR 4;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; INNATE IMMUNITY; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 72649106903     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp228     Document Type: Article

References (44)

1. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyo-sitis patients is associated with disease activity. Mol Med 2007; 13: 59-68.
2. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol 2007; 8: 172-180
3. Baranzini SE, Mousavi P, Rio J, Caillier SJ, Stillman A, Villoslada P, et al. Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol 2005; 3: e2.
4. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 2004; 279: 45194-45207
5. Barrier A, Lemoine A, Boelle PY, Tse C, Brault D, Chiappini F, et al. Colon cancer prognosis prediction by gene expression profiling. Oncogene 2005; 24: 6155-6164
6. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 1995; 57: 289-300.
7. Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med 1993; 178: 1655-1663
8. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernandez O, Brassat D, et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337-344
9. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796-805.
10. Der SD, Zhou A, Williams BRG, Silverman RH. Identification of genes differentially regulated by interferon a, p, or y using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95: 15623-15628
11. Dhodapkar KM, Banerjee D, Connolly J, Kukreja A, Matayeva E, Veri MC, et al. Selective blockade of the inhibitory Fc{gamma} receptor (Fc{gamma}RIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med 2007; 204: 1359-1369
12. Gneiss C, Tripp P, Reichartseder F, Egg R, Ehling R, Lutterotti A, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 2006; 12: 731-737
13. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006; 103: 2770-2775
14. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003; 4: 177-186
15. Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 2005; 42: 702-710
16. Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hovelmeyer N, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 2005; 11: 146-152
17. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264
18. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294
19. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-869
20. Karni A, Abraham M, Monsonego A, Cai G, Freeman GJ, Hafler D, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006; 177: 4196-5202.
21. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3958-3967
22. Krumbholz M, Faber H, Steinmeyer F, Hoffmann LA, Kümpfel T, Pellkofer H, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008; 131: 1455-1463
23. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14: 461-470
24. Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, et al. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immu-notherapy. J Natl Cancer Inst 2004; 96: 1331-1342
25. Leszczyniecka M, Su ZZ, Kang DC, Sarkar D, Fisher PB. Expression regulation and genomic organization of human polynucleotide phos-phorylase, hPNPase(old-35), a Type I interferon inducible early response gene. Gene 2003; 316: 143-156
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408
27. Minagar A, Adamashvili I, Kelley RE, Gonzalez-Toledo E, McLarty J, Smith SJ. Saliva soluble HLA as a potential marker of response to interferon-beta1a in multiple sclerosis: a preliminary study. J Neuroinflammation 2007; 4: 16.
28. Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, Raasch J, et al. Distinct and nonredundant in vivo functions of ifnar on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008; 28: 675-686
29. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504
30. Radvanyi LG, Banerjee A, Weir M, Messner H. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand J Immunol 1999; 50: 499-509.
31. Rio J, Nos C, Tintoré M, Borras C, Galan I, Comabella M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002; 52: 400-406
32. Rio J, Nos C, Tintoré M, Tellez N, Galan I, Pelayo R, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-352
33. Réo J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008; 14: 479-484
34. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007; 131: 1124-1136
35. Severa M, Remoli ME, Giacomini E, Ragimbeau J, Lande R, Uzé G, et al. Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression. J Leukoc Biol 2006; 79: 1286-1294
36. Severa M, Remoli ME, Giacomini E, Annibali V, Gafa V, Lande R, et al. Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells. J Immunol 2007; 178: 6208-6216
37. Soilu-Hanninen M, Laaksonen M, Hanninen A, Eralinna JP, Panelius M. Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in multiple sclerosis. J Neuroimmunol 2005; 167: 175-182
38. Stewart TA. Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev 2003; 14: 139-154
39. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology 2006; 45: 694-702
40. The Interferon b Multiple Sclerosis Study Group.Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661
41. Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, Park PJ. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci USA 2005; 102: 13544-13549
42. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, Hooper T, et al. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 2006; 7: 522-531
43. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007; 66: 1008-1014
44. Watzinger F, Suda M, Preuner S, Baumgartinger R, Ebner K, Baskova L, et al. Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients. J Clin Microbiol 2004; 42: 5189-5198